Introduction
Flupirtine (FLU) is an aminopyridine drug (ethyl {2-amino-6-[(4-54 fluorobenzyl)amino]pyridin-3-yl}carbamate) approved in Europe in 1984 for the treatment of pain 55 (Kumar et al., 2013) . FLU is a centrally acting analgesic with a mechanism of action unlike that of 56 opiates and non-steroidal anti-inflammatory drugs (NSAIDs); it is active with a favourable 57 tolerability, and has no antipyretic or anti-inflammatory effects (Devulder, 2010) . FLU was the first 58 drug to be recognised in the class of 'Selective Neuronal Potassium Channel Openers' (SNEPCOs) 59 (Kornhuber et al., 1999) . acute to moderate pain, such as post-operative pain, trauma and dysmenorrhoea (Heusinger, 1987) . While there is a substantial body of evidence on the efficacy of FLU in humans, only a small 90 number of studies on the analgesic effect of FLU in laboratory animals are to be found in the 91 literature (Gordon et al., 1987; Schwarz et al., 1995; Nielsen et al., 2004) and its pharmacokinetic 92 profiles in cats (de Vito et al., 2014a) and dogs (De Vito et al., 2014b) Wilk test). All analyses were conducted using GraphPad InStat (GraphPad Software). In all 188 experiments, differences were considered significant if P < 0.05.
190

Results
191
The HPLC method was re-validated using horse plasma. Briefly, FLU was linear (r 2 >0.99) in 192 the range 10-1500 ng/mL. When samples exceeded the upper limit of the range, they were re-
193
analysed after appropriate dilution. The intra-day repeatability was measured as coefficient of 194 variation and was < 5.3 %, whereas accuracy, measured as closeness to the concentration added on 195 the same replicates, was < 6.2 %.
Immediately after IV injection of the drug, 2/6 horses showed adverse effects including 198 muscle twitching, head shaking and agitation but they resolved spontaneously within 5 min. No 199 behavioural changes or alterations in health parameters (heart rate, rectal temperature and intestinal 200 sounds) were observed in the remaining animals during or up to 7 days after the study. Health 201 parameters and behaviour were evaluated once a day and were found to be normal. Table 1 .
After pharmacokinetic simulation of PO multiple dosing, it was found that if the drug is 220 administered once every 24 h the steady state would be achieved after the second administration.
221
The oral dose that theoretically should be administered to horses in order to achieve similar C max
222
and AUC values to those reported with clinical doses in humans is 2.6 mg/kg (Fig. 2) indicated that this value is exceeded for over 9 h and 15 h following administration (Fig. 2 ) of 2.6 227 and 5 mg/kg of FLU, respectively. cancer-associated pain (Luben et al., 1994; Kolosov et al., 2012) . FLU also produced a significant 238 increase in morphine anti-nociception when the two drugs were administered in combination in 239 different rat models of pain (Goodchild et al., 2008; Capuano et al., 2011) . If the sparing opioid 240 effect is also evident in horses, this active ingredient could play an important role in multimodal 241 analgesic therapy in order to avoid moderately high regimens of opioids.
242
either species-specific pharmacokinetic data or prior drug experience in the target species (Hunter, 245 2010). In the present study, an approach based on data extrapolated from humans rather than an 246 allometric calculation of the dose was preferred. Both the approaches share the assumption that 247 species differences in pharmacodynamics are clinically negligible. The oral dose administered in 248 the present study (5 mg/kg) was about 3  higher than the minimum dose reported in human clinical 249 practice (100 mg/subject/day). However, it was still within the recommended human clinical range 250 (100-400 mg/subject/day; Devulder, 2010). (Chiou et al., 2000; Kim et al., 2014 Kim et al., , 2015 .
284
Although FLU has been used in the treatment of acute and chronic states in humans for 25 285 years, no minimal effective concentration for pain relief has yet been reported. However, it is 286 noteworthy that in horses (despite the lower oral F% than in humans) a dose of 5 mg/kg PO 287 produced FLU plasma concentrations higher that the plasma concentrations produced by the PO 288 clinical dose (100 mg/subject/day) reported in humans (Hlavica and Niebch, 1985) . After (Nickel, 1987; Gordon et al., 1987) . The drug plasma EC 300 calculated after the simulation is exceeded for over 9 h and 15 h, after 2.6 and 5 mg/kg FLU oral 301 administration, respectively, suggesting a long lasting therapeutic effect of the drug. It is 302 emphasised here that both the dose and EC are still theoretical and unconfirmed and further PK/PD 303 studies are required.
305
Following PO administration of FLU, horses showed mean terminal plasma elimination half-306 lives in between those reported in cats (13.6 h) and dogs (7.1 h) (De Vito et al., 2014a,b) . This is 307 consistent with the clearance value of FLU in horses which is smaller than that reported in dogs Kim, T.W., della Rocca, G., Di Salvo, A., Ryschanova, R., Micaela, S., Giorgi, M., 2015. Methling, K., Reszka, P., Lalk, M., Vrana, O., Scheuch, E., Siegmund, W., Terhaag, B., Bednarski, 
